Winner Medical(SZ:300888) Zheng Quan Zhi Xing·2025-08-21 12:13Core Viewpoint - The legal opinion letter from Beijing Zhonglun (Shenzhen) Law Firm confirms that the adjustments to the stock incentive plan of Shengjian Medical Supplies Co., Ltd. have received necessary approvals and comply with relevant laws and regulations [2][16]. Group 1: Legal Framework and Compliance - The law firm was commissioned to provide legal advice regarding the 2024 restricted stock incentive plan for Shengjian Medical [2]. - The legal opinion is based on various Chinese laws, including the Company Law and Securities Law, as well as regulations from the China Securities Regulatory Commission and the Shenzhen Stock Exchange [2][4]. - The law firm asserts that the company has provided complete and truthful documentation necessary for the issuance of the legal opinion [4][6]. Group 2: Adjustment of Stock Grant Price - The stock grant price for the incentive plan has been adjusted from 15.39 yuan per share to 14.69 yuan per share due to a cash dividend distribution [10][14]. - The adjustment method follows the formula: P = P0 - V, where P0 is the original grant price and V is the cash dividend per share [13][14]. - The company’s annual general meeting approved a cash dividend of 145,582,452 yuan, and the board of directors later approved a cash dividend of 262,048,413.60 yuan for the 2025 interim distribution [10][11]. Group 3: Information Disclosure Obligations - The company is required to timely disclose relevant documents related to the adjustments made to the stock incentive plan [14][16]. - The law firm emphasizes that the company must continue to fulfill its information disclosure obligations as the incentive plan progresses [14][16].